Table 1.
Demographic and clinical data of vaccinated MS patients.
| Study Population (n = 211) | |
|---|---|
| Duration of follow-up at data cut-off date, days | |
| Median | 66 |
| 25–75 IQR | 54–84 |
| Gender, n (%) | |
| Female | 131 (62.0%) |
| Male | 80 (37.9%) |
| Age group, n (%) | |
| 18–55 years | 121 (57.3%) |
| >55 years | 90 (42.6%) |
| Disease duration, years | |
| Median | 16.65 |
| 25–75 IQR | 9.48–25.85 |
| Disability by EDSS, n (%) | |
| ⩽3.0 | 93 (44.1%) |
| 3.5–5.5 | 50 (23.7%) |
| ⩾6.0 | 68 (32.2%) |
| Disease type, n (%) | |
| CIS | 7 (3.3%) |
| RRMS | 126 (59.7%) |
| SPMS | 42 (19.9%) |
| PPMS | 36 (17.0%) |
| IMD treatment, n (%) | |
| Untreated | 53 (25.1%) |
| Beta-interferons (1a and 1b) | 6 (0.3%) |
| Glatiramer acetate | 2 (0.9%) |
| Teriflunomide | 19 (9.0%) |
| Dimethyl fumarate | 9 (4.3%) |
| Natalizumab | 17 (8.0%) |
| Fingolimod | 25 (11.8%) |
| Ocrelizumab | 65 (30.8%) |
| Alemtuzumab | 4 (1.9%) |
| Cladribine | 7 (3.3%) |
| Rituximab | 1 (0.5%) |
| IVIg | 3 (1.4%) |
EDSS: Expanded Disability Status Scale; IQR: interquartile range; IMD: immunomodulatory drug; IVIg: intravenous immunoglobulin immunoglobulin; CIS: Clinically Isolated Syndrome; RRMS: Relapsing Remmiting Multiple Sclerosis; SPMS: Secondary Progressive Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis.